8-K: MedMen Finalizes Arizona Asset Sale to Mint Cannabis, Nevada Deal Pending

MedMen has completed the sale of its Arizona operations to Mint Cannabis, while the sale of its Nevada assets is still pending regulatory approval.

Summary

• MedMen has successfully sold its Arizona business operations to an affiliate of Mint Cannabis for approximately $14 million, subject to adjustments.
• The sale includes MedMen's wholly-owned operating subsidiary in Arizona and its two operating dispensaries in Clark County, Nevada.
• The Nevada asset sale is still pending and requires regulatory approval.
• The total consideration for both the Arizona and Nevada assets includes a minimum of $24 million in cash, subject to adjustments, and $5.5 million in short-term seller notes, also subject to adjustments.
• The company has been moved from the OTCQB market to the OTC Expert Market due to not filing its annual and quarterly reports.
• A cease trade order has been issued by Canadian securities regulators due to the company's failure to file required reports.

Sentiment

Score: 4

Explanation: The document contains both positive and negative elements. The sale of assets is a positive step, but the move to the OTC Expert Market and the cease trade order are significant concerns. Overall, the sentiment is negative due to the regulatory and financial issues.

Positives

• The sale of the Arizona assets provides MedMen with approximately $14 million in cash, which can be used to improve its financial position.
• The divestiture of non-core operations allows MedMen to focus on its core markets and optimize its operational footprint.

Negatives

• The company has been moved from the OTCQB market to the OTC Expert Market, which may reduce investor confidence.
• The cease trade order in Canada restricts trading of MedMen securities, which could negatively impact shareholders.
• The company has not filed its annual and quarterly reports, which indicates potential financial and operational issues.

Risks

• The pending sale of Nevada assets is subject to regulatory approval, which may be delayed or denied.
• The company's failure to file required reports could lead to further regulatory actions and penalties.
• The move to the OTC Expert Market and the cease trade order could negatively impact the company's ability to raise capital.
• The company's financial statements for the year ended July 1, 2023 and the quarter ended September 30, 2023 are not yet complete and filed with the SEC.

Future Outlook

The company intends to reapply to the OTCQB market once it files its annual and quarterly reports and meets all eligibility requirements. The sale of the Nevada assets is pending regulatory approval.

Management Comments

• Ellen Deutsch Harrison, MedMen's CEO, stated that the divestiture of non-core operations enables the Company to optimize its go-forward operational footprint.

Industry Context

The sale of assets reflects a trend of consolidation and strategic realignment within the cannabis industry, as companies focus on core markets and improve financial stability. MedMen's move to divest non-core assets is consistent with this trend.

Comparison to Industry Standards

• MedMen's decision to sell assets is similar to other cannabis companies that have divested non-core operations to improve financial performance.
• The move to the OTC Expert Market is a negative development, as it indicates a failure to meet reporting requirements, which is not in line with industry best practices.
• The cease trade order in Canada is a significant issue, as it restricts trading of the company's securities, which is not a common occurrence for established cannabis companies.

Stakeholder Impact

• Shareholders are negatively impacted by the move to the OTC Expert Market and the cease trade order.
• Employees in Arizona are impacted by the sale of operations to Mint Cannabis.
• Customers in Arizona will now be served by Mint Cannabis.

Next Steps

• MedMen needs to complete the sale of its Nevada assets.
• MedMen needs to file its annual and quarterly reports to regain compliance with listing requirements.
• MedMen needs to reapply to the OTCQB market.
• MedMen needs to address the cease trade order in Canada.

Key Dates

Keywords

MedMen, Mint Cannabis, asset sale, Arizona, Nevada, cannabis, dispensary, OTCQB, OTC Expert Market, cease trade order, regulatory approval, financial reports